We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BAUSCH & LOMB DID NOT REPORT ADVERSE EVENTS FOR MOISTURE LOC, FDA SAYS

BAUSCH & LOMB DID NOT REPORT ADVERSE EVENTS FOR MOISTURE LOC, FDA SAYS

May 17, 2006

Bausch & Lomb failed to submit a medical device report (MDR) detailing 35 serious injury reports of Fusarium keratitis -- the most common form of fungal keratitis, an infection of the cornea -- in contact lens wearers using the firm's ReNu with MoistureLoc product in Singapore, the FDA said in a Form 483 issued to the company May 15.

Singapore's Minister of Health reported the incidents to the company in February, but none of the complaints had been reported to the FDA as of April 7, the agency said. Five other complaints of Fusarium infection were reported to the firm in July 2005 but had not been reported to the agency as of May 9. The firm also did not report its removal of ReNu with MoistureLoc or its Multi-Purpose solution from the market in Singapore and Hong Kong in February.

The company has been subject to a number of lawsuits from people claiming injury from the product. A New York man filed a lawsuit against Bausch & Lomb in federal court April 20, accusing the company of engaging in deceptive marketing practices and failing to publicly disclose an inherent defect in its ReNu with MoistureLoc solution that makes the product susceptible to Fusarium keratitis. Nelson Huie has alleged the company knew of the link between the product and increased incidences of Fusarium in Asia as early as February, but did not suspend sales of the product in the U.S. until cases of the infection became public.

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

  • FDA Expands Approval of Pfizer and Myovant’s Myfembree to Include Endometriosis

  • FDA Provides Update on Haimen Shengbang Laboratory’s Recall of Its Viral Transport Media Containers

  • FDA Issues EUA for Monkeypox Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing